NASDAQ:FGENFibroGen Stock Price, Forecast & News

FibroGen's stock was trading at $35.40 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, FGEN stock has increased by 27.7% and is now trading at $45.19.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for FibroGen.

FibroGen is scheduled to release its next quarterly earnings announcement on Monday, November 9th 2020.
View our earnings forecast for FibroGen.

FibroGen Inc (NASDAQ:FGEN) posted its quarterly earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.95) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.64) by $0.31. The biopharmaceutical company had revenue of $42.90 million for the quarter, compared to analyst estimates of $48.29 million. FibroGen had a negative net margin of 287.01% and a negative return on equity of 57.40%. The business's quarterly revenue was down 77.6% compared to the same quarter last year. During the same period in the prior year, the business posted $1.26 EPS.
View FibroGen's earnings history.

5 brokerages have issued twelve-month target prices for FibroGen's stock. Their forecasts range from $40.00 to $84.00. On average, they anticipate FibroGen's share price to reach $58.40 in the next year. This suggests a possible upside of 29.2% from the stock's current price.
View analysts' price targets for FibroGen.

News stories about FGEN stock have been trending negative on Wednesday, InfoTrie reports. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. FibroGen earned a coverage optimism score of -2.2 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days.
View the latest news about FibroGen.

Some companies that are related to FibroGen include Alnylam Pharmaceuticals (ALNY), Horizon Therapeutics (HZNP), Catalent (CTLT), Teva Pharmaceutical Industries (TEVA), Sarepta Therapeutics (SRPT), GRIFOLS S A/S (GRFS), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Dr.Reddy's Laboratories (RDY), Ono Pharmaceutical (OPHLF), Mylan (MYL), Ascendis Pharma A/S (ASND), Ionis Pharmaceuticals (IONS), Perrigo (PRGO) and Jazz Pharmaceuticals (JAZZ).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ).

(FGEN) raised $146 million in an IPO on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

FibroGen's stock is owned by a variety of institutional and retail investors. Top institutional investors include First Trust Advisors LP (1.89%), Bank of New York Mellon Corp (1.67%), Principal Financial Group Inc. (0.29%), Prudential Financial Inc. (0.29%), Candriam Luxembourg S.C.A. (0.24%) and New York State Common Retirement Fund (0.24%). Company insiders that own FibroGen stock include Christine Chung, Elias Kouchakji, Enrique A Conterno, James A Schoeneck, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura.
View institutional ownership trends for FibroGen.

FGEN stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, UBS Group AG, Prudential Financial Inc., Barclays PLC, Alps Advisors Inc., WINTON GROUP Ltd, Candriam Luxembourg S.C.A., and Envestnet Asset Management Inc.. Company insiders that have sold FibroGen company stock in the last year include Christine Chung, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Thomas B Neff, and Thomas F Kearns Jr.
View insider buying and selling activity for FibroGen.

FGEN stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, First Trust Advisors LP, Principal Financial Group Inc., Hudson Bay Capital Management LP, SG Americas Securities LLC, Mutual of America Capital Management LLC, Swiss National Bank, and Rafferty Asset Management LLC.
View insider buying and selling activity for FibroGen.

Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of FGEN stock can currently be purchased for approximately $45.19.

FibroGen has a market capitalization of $4.08 billion and generates $256.58 million in revenue each year. The biopharmaceutical company earns $-76,970,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. FibroGen employs 461 workers across the globe.

The official website for FibroGen is www.fibrogen.com.

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]